Going it alone: possible outcomes for life sciences

The UK is aiming to leave the EU by March 2019. This means a lot of things are set to change in the next two years.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

6 August 2026 A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.

Careers

Brown Rudnick lands largest lateral IP team hire in firm history

6 August 2026 The 34-lawyer group prompts the launch of a Silicon Valley office and strengthens the firm’s technology, life sciences and global litigation capabilities.

Regulation & Industry

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

5 August 2026 From advising pioneering startups to championing women in the profession, Fran Salisbury of Mewburn Ellis has spent her career making innovation count. Here, she reflects on the challenges, opportunities and motivations that continue to drive her.

More features

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

Patent litigator joins Baker Botts in London as UPC grows in significance

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

Where Big Pharma is betting big in the M&A boom

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

Going it alone: possible outcomes for life sciences

More on this story

Editor's picks

Editor's picks

More features